SCHEMBL22714731

SCHEMBL22714731

COc1cc(-c2ncc(C)cn2)cc2c(NCc3nnc(C)s3)ncnc12

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 13/20 0.41
ALDH1A1 P00352 3/20 0.38
HTT P42858 2/20 0.38
KDM4E B2RXH2 1/20 0.38
CLK4 Q9HAZ1 3/20 0.37
EGFR P00533 1/20 0.36
CD38 P28907 1/20 0.36
USP2 O75604 2/20 0.36
LMNA P02545 2/20 0.36
CYP1A2 P05177 2/20 0.36
CYP3A4 P08684 2/20 0.36
CYP2D6 P10635 2/20 0.36
TSHR P16473 2/20 0.36
MAPK1 P28482 2/20 0.36
CYP2C19 P33261 2/20 0.36
HSD17B10 Q99714 2/20 0.36
HPGD P15428 1/20 0.35
CYP2C9 P11712 1/20 0.35
HIF1A Q16665 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22714830 0.85 PDE5A (0.40) PDE5AALDH1A1HTTKDM4ECLK4
SCHEMBL24478553 0.80 CLK4 (0.43) PDE5AALDH1A1HTTKDM4ECLK4
SCHEMBL29481264 0.80 CLK4 (0.43) PDE5AALDH1A1HTTKDM4ECLK4
SCHEMBL29676245 0.79 EGFR (0.38) EGFRCD38
SCHEMBL28685033 0.79 EGFR (0.38) EGFRCD38
SCHEMBL22732309 0.78 PDE5A (0.48) PDE5AALDH1A1HTTKDM4ECLK4
SCHEMBL29676453 0.78 PDE5A (0.48) PDE5AALDH1A1HTTKDM4ECLK4
SCHEMBL22732451 0.78 PDE5A (0.40) PDE5AALDH1A1HTTKDM4ECLK4
SCHEMBL22732296 0.77 PDE5A (0.45) PDE5AALDH1A1HTTKDM4ECLK4
SCHEMBL29676300 0.77 PDE5A (0.45) PDE5AALDH1A1HTTKDM4ECLK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12466820-B2 Amino quinazoline derivatives as P2X3 inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2025-11-11 US claimed
CN-113891745-B As P2X3Aminoquinazoline derivatives of inhibitors 奇斯药制品公司 2024-05-07 CN claimed
US-20220227749-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS CHARLES RIVER LABORATORIES, INC. 2022-07-21 US claimed
EP-3976180-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS Chiesi Farmaceutici S.p.A. (IT) 2022-04-06 EP claimed
CN-113891745-A As P2X3Aminoquinazoline derivatives as inhibitors 奇斯药制品公司 2022-01-04 CN claimed
WO-2020239952-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2020-12-03 WO claimed
US-12466820-B2 Amino quinazoline derivatives as P2X3 inhibitors CHIESI FARMACEUTICI S.P.A. (IT) 2025-11-11 US disclosed
US-20220227749-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS CHARLES RIVER LABORATORIES, INC. 2022-07-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220227749-A1 AMINO QUINAZOLINE DERIVATIVES AS P2X3 INHIBITORS P2RX3, P2RX5, P2RX1 PDE5A 103/4885ALDH1A1 1918/4885HTT 4638/4885
US-12466820-B2 Amino quinazoline derivatives as P2X3 inhibitors P2RX3, P2RX5, P2RX1 PDE5A 103/4885ALDH1A1 1918/4885HTT 4638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.